290 related articles for article (PubMed ID: 36389798)
1. Identify the immune characteristics and immunotherapy value of CD93 in the pan-cancer based on the public data sets.
Guo A; Zhang J; Tian Y; Peng Y; Luo P; Zhang J; Liu Z; Wu W; Zhang H; Cheng Q
Front Immunol; 2022; 13():907182. PubMed ID: 36389798
[TBL] [Abstract][Full Text] [Related]
2. Large-Scale Single-Cell and Bulk Sequencing Analyses Reveal the Prognostic Value and Immune Aspects of CD147 in Pan-Cancer.
Zhang J; Wang Z; Zhang X; Dai Z; Zhi-Peng W; Yu J; Peng Y; Wu W; Zhang N; Luo P; Zhang J; Liu Z; Feng S; Zhang H; Cheng Q
Front Immunol; 2022; 13():810471. PubMed ID: 35464411
[TBL] [Abstract][Full Text] [Related]
3. CD93 orchestrates the tumor microenvironment and predicts the molecular subtype and therapy response of bladder cancer.
Zheng X; Xu H; Lin T; Tan P; Xiong Q; Yi X; Qiu S; Yang L; Shen B; Ai J; Wei Q
Comput Biol Med; 2022 Aug; 147():105727. PubMed ID: 35785664
[TBL] [Abstract][Full Text] [Related]
4. CD93 Correlates With Immune Infiltration and Impacts Patient Immunotherapy Efficacy: A Pan-Cancer Analysis.
Zhang Z; Zheng M; Ding Q; Liu M
Front Cell Dev Biol; 2022; 10():817965. PubMed ID: 35242761
[No Abstract] [Full Text] [Related]
5. Pan-Cancer Analysis Identified CD93 as a Valuable Biomarker for Predicting Patient Prognosis and Immunotherapy Response.
Tong W; Wang G; Zhu L; Bai Y; Liu Z; Yang L; Wu H; Cui T; Zhang Y
Front Mol Biosci; 2021; 8():793445. PubMed ID: 35265666
[No Abstract] [Full Text] [Related]
6. Identification of CD73 as a Novel Biomarker Encompassing the Tumor Microenvironment, Prognosis, and Therapeutic Responses in Various Cancers.
Tang K; Zhang J; Cao H; Xiao G; Wang Z; Zhang X; Zhang N; Wu W; Zhang H; Wang Q; Xu H; Cheng Q
Cancers (Basel); 2022 Nov; 14(22):. PubMed ID: 36428755
[TBL] [Abstract][Full Text] [Related]
7. CD93 promotes β1 integrin activation and fibronectin fibrillogenesis during tumor angiogenesis.
Lugano R; Vemuri K; Yu D; Bergqvist M; Smits A; Essand M; Johansson S; Dejana E; Dimberg A
J Clin Invest; 2018 Aug; 128(8):3280-3297. PubMed ID: 29763414
[TBL] [Abstract][Full Text] [Related]
8. CD93 overexpresses in liver hepatocellular carcinoma and represents a potential immunotherapy target.
Jiang Q; Kuai J; Jiang Z; Que W; Wang P; Huang W; Ding W; Zhong L
Front Immunol; 2023; 14():1158360. PubMed ID: 37483608
[TBL] [Abstract][Full Text] [Related]
9. Dissecting the role of cancer-associated fibroblast-derived biglycan as a potential therapeutic target in immunotherapy resistance: A tumor bulk and single-cell transcriptomic study.
Zheng S; Liang JY; Tang Y; Xie J; Zou Y; Yang A; Shao N; Kuang X; Ji F; Liu X; Tian W; Xiao W; Lin Y
Clin Transl Med; 2023 Feb; 13(2):e1189. PubMed ID: 36772945
[TBL] [Abstract][Full Text] [Related]
10. Multi-omics profiling and digital image analysis reveal the potential prognostic and immunotherapeutic properties of CD93 in stomach adenocarcinoma.
Wu B; Fu L; Guo X; Hu H; Li Y; Shi Y; Zhang Y; Han S; Lv C; Tian Y
Front Immunol; 2023; 14():984816. PubMed ID: 36761750
[TBL] [Abstract][Full Text] [Related]
11. Structural insight into CD93 recognition by IGFBP7.
Xu Y; Sun Y; Zhu Y; Song G
Structure; 2024 Mar; 32(3):282-291.e4. PubMed ID: 38218180
[TBL] [Abstract][Full Text] [Related]
12. Identify the Prognostic and Immune Profile of VSIR in the Tumor Microenvironment: A Pan-Cancer Analysis.
Liu Y; Zhang J; Wang Z; Zhang X; Dai Z; Wu W; Zhang N; Liu Z; Zhang J; Luo P; Wen Z; Yu J; Zhang H; Yang T; Cheng Q
Front Cell Dev Biol; 2022; 10():821649. PubMed ID: 35493077
[TBL] [Abstract][Full Text] [Related]
13. CD93 serves as a potential biomarker of gastric cancer and correlates with the tumor microenvironment.
Li Z; Zhang XJ; Sun CY; Fei H; Li ZF; Zhao DB
World J Clin Cases; 2023 Feb; 11(4):738-755. PubMed ID: 36818626
[TBL] [Abstract][Full Text] [Related]
14. Identification and characterization of prognosis-related genes in the tumor microenvironment of esophageal squamous cell carcinoma.
Qu J; Zhao Q; Yang L; Ping Y; Zhang K; Lei Q; Liu F; Zhang Y
Int Immunopharmacol; 2021 Jul; 96():107616. PubMed ID: 34162127
[TBL] [Abstract][Full Text] [Related]
15. CD93 and dystroglycan cooperation in human endothelial cell adhesion and migration adhesion and migration.
Galvagni F; Nardi F; Maida M; Bernardini G; Vannuccini S; Petraglia F; Santucci A; Orlandini M
Oncotarget; 2016 Mar; 7(9):10090-103. PubMed ID: 26848865
[TBL] [Abstract][Full Text] [Related]
16. CD93 a potential player in cytotrophoblast and endothelial cell migration.
Fantone S; Tossetta G; Di Simone N; Tersigni C; Scambia G; Marcheggiani F; Giannubilo SR; Marzioni D
Cell Tissue Res; 2022 Jan; 387(1):123-130. PubMed ID: 34674045
[TBL] [Abstract][Full Text] [Related]
17. Dissecting the CD93-Multimerin 2 interaction involved in cell adhesion and migration of the activated endothelium.
Galvagni F; Nardi F; Spiga O; Trezza A; Tarticchio G; Pellicani R; Andreuzzi E; Caldi E; Toti P; Tosi GM; Santucci A; Iozzo RV; Mongiat M; Orlandini M
Matrix Biol; 2017 Dec; 64():112-127. PubMed ID: 28912033
[TBL] [Abstract][Full Text] [Related]
18. The circadian rhythm key gene
Wu G; Ren H; Hu Q; Ma H; Chen H; Zhou L; Xu K; Ding L
Front Immunol; 2023; 14():1115809. PubMed ID: 37275880
[TBL] [Abstract][Full Text] [Related]
19. Pan-cancer analysis of N4-acetylcytidine adaptor THUMPD1 as a predictor for prognosis and immunotherapy.
Li K; Liu J; Yang X; Tu Z; Huang K; Zhu X
Biosci Rep; 2021 Dec; 41(12):. PubMed ID: 34762107
[TBL] [Abstract][Full Text] [Related]
20. Role of CD93 in Health and Disease.
Tossetta G; Piani F; Borghi C; Marzioni D
Cells; 2023 Jul; 12(13):. PubMed ID: 37443812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
